Canada - English - Health Canada

lederle cyanamid canada inc. - leucovorin (leucovorin calcium) - powder for solution - 50mg - leucovorin (leucovorin calcium) 50mg - antidotes

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - doxycycline (unii: n12000u13o) (doxycycline anhydrous - unii:334895s862) - doxycycline anhydrous 50 mg - to reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline monohydrate capsules and other antibacterial drugs, doxycycline monohydrate capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline is indicated for the treatment of the following infections:     rocky mountain spotted fever, typhus fever and the typhus group, q fever, rickettsialpox, and tick fevers caused by rickettsiae .     respiratory tract infections caused by mycoplasma pneumoniae .     lymphogranuloma venereum caused by chlamydia trachomatis .     psittacosis (ornithosis) caused by chlamydophila psittaci .     trachoma caused by chlamydia trachomatis , alt

United States - English - NLM (National Library of Medicine)

boiron - hamamelis virginiana root bark/stem bark (unii: t7s323pkjs) (hamamelis virginiana root bark/stem bark - unii:t7s323pkjs) - hemorrhoids with bursting sensation* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr) - in the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. if test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. rifampin is indicated in the treatment of all forms of tuberculosis. a three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide is recommended in the initial phase of short-course therapy which is usually continued for 2 months. the advisory council for the elimination of tuberculosis, the american thoracic society, and centers for disease control and prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (inh), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of inh resistance is very low. the need for a fourth drug should be reassessed when the results of susceptibility testing are known. if community rates of inh resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. following the initial phase, treatment should be continued with rifampin and isoniazid for at least 4 months. treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is hiv positive. rifampin iv is indicated for the initial treatment and retreatment of tuberculosis when the drug cannot be taken by mouth. rifampin is indicated for the treatment of asymptomatic carriers of neisseria meningitidis to eliminate meningococci from the nasopharynx. rifampin is not indicated for the treatment of meningococcal infection because of the possibility of the rapid emergence of resistant organisms (see warnings). rifampin should not be used indiscriminately, and, therefore, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed for establishment of the carrier state and the correct treatment. so that the usefulness of rifampin in the treatment of asymptomatic meningococcal carriers is preserved, the drug should be used only when the risk of meningococcal disease is high. to reduce the development of drug-resistant bacteria and maintain the effectiveness of rifampin and other antibacterial drugs, rifampin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. rifampin capsules are contraindicated in patients with a history of hypersensitivity to rifampin or any of the components, or to any of the rifamycins. (see warnings  ). rifampin is contraindicated in patients who are also receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity. (see   precautions, drug interactions ). rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance. rifampin is contraindicated in patients receiving praziquantel since therapeutically effective blood levels of praziquantel may not be achieved. in patients receiving rifampin who need immediate treatment with praziquantel alternative agents should be considered. however, if treatment with praziquantel is necessary, rifampin should be discontinued 4 weeks before administration of praziquantel. treatment with rifampin can then be restarted one day after completion of praziquantel treatment. rifampin is contraindicated in patients receiving lurasidone. concomitant use of lurasidone with strong cyp3a4 inducers (e.g., rifampin) decreased the exposure of lurasidone compared to the use of lurasidone alone. (see precautions , drug interactions ).

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - 1. sedative 2. anticonvulsant - for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance phenobarbital is a schedule iv drug. dependence barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than twofold. as this occurs,the margin between intoxicating dosage and fatal dosage becomes smaller. symptoms of acute intoxication with barbiturates include unsteady gait, slurred speech, and sustained nystagmus. mental signs of chronic intoxication include confusion, poor judgment, irritability, insomnia, and somatic complaints. symptoms of barbiturate dependence are similar to those of chronic alcoholism. if an individual appears to be intoxicated with alcohol to a degree that is radically disproportionate to the amount of alcohol in his or her blood, the use of barbiturates should be suspected. the lethal dose of a barbiturate is far less if alcohol is also ingested. the symptoms of barbiturate withdrawal can be severe and may cause death. minor withdrawal symptoms may appear 8 to 12 hours after the last dose of a barbiturate. these symptoms usually appear in the following order: anxiety, muscle twitching, tremor of hands and fingers, progressive weakness, dizziness, distortion in visual perception, nausea, vomiting, insomnia, and orthostatic hypotension. major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of barbiturates. the intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. individuals susceptible to barbiturate abuse and dependence include alcoholics and opiate abusers as well as other sedative-hypnotic and amphetamine abusers. drug dependence on barbiturates arises from repeated administration of a barbiturate or agent with barbiturate-like effect on a continuous basis, generally in amounts exceeding therapeutic dose levels. the characteristics of drug dependence on barbiturates include: (a) a strong desire or need to continue taking the drug; (b) a tendency to increase the dose; (c) a psychic dependence on the effects of the drug related to subjective and individual appreciation of those effects; and (d) a physical dependence on the effects of the drug, requiring its presence for maintenance of homeostasis and resulting in a definite, characteristic, and self-limited abstinence syndrome when the drug is withdrawn. treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. in all cases, withdrawal requires an extended period of time. one method involves substituting a 30-mg dose of phenobarbital for each 100- to 200-mg dose of barbiturate that the patient has been taking. the total daily amount of phenobarbital is then administered in 3 or 4 divided doses, not to exceed 600 mg daily. if signs of withdrawal occur on the first day of treatment, a loading dose of 100 to 200 mg of phenobarbital may be administered im in addition to the oral dose. after stabilization on phenobarbital, the total daily dose is decreased by 30 mg/day as long as withdrawal is proceeding smoothly. a modification of this regimen involves initiating treatment at the patient’s regular dosage level and decreasing the daily dosage by 10% if tolerated by the patient. infants who are physically dependent on barbiturates may be given phenobarbital, 3 to 10 mg/kg/day. after withdrawal symptoms (hyperactivity, disturbed sleep, tremors, and hyperreflexia) are relieved, the dosage of phenobarbital should be gradually decreased and completely withdrawn over a 2-week period.

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin tablets are indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin tablets are indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin tablets are indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metron

United States - English - NLM (National Library of Medicine)

parfums christian dior - ensulizole (unii: 9yq9di1w42) (ensulizole - unii:9yq9di1w42), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w) - - helps prevent sunburn. - if used as directed with other sun protection measures ( ), decreases the risk of skin cancer and early skin aging caused by the sun.  see directions

United States - English - NLM (National Library of Medicine)

nelco laboratories, inc. - paspalum notatum pollen (unii: v003shb7vk) (paspalum notatum pollen - unii:v003shb7vk) - paspalum notatum pollen 10000 [pnu] in 1 ml - allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. the use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. allergenic extracts should not be used if the patient has asthma, cardiovascular disease, emphysema, diabetes, bleeding diathesis or pregnancy, unless a specific diagnosis of t

United States - English - NLM (National Library of Medicine)

iba inc. - calcium gluconate (unii: sqe6vb453k) (calcium cation - unii:2m83c4r6zb) - calcium gluconate 23 g in 100 ml - to be used as an aid in the treatment of parturient paresis (milk fever) in cattle.

United States - English - NLM (National Library of Medicine)

bayer healthcare, llc animal health division - imidacloprid (unii: 3bn7m937v8) (imidacloprid - unii:3bn7m937v8) - imidacloprid 7.5 mg - advantus™ kills adult fleas and is indicated for the treatment of flea infestations on dogs and puppies 10 weeks of age and older and weighing 4 pounds or greater.